The short answer on durability

For most patients with suitable focal knee cartilage defects, functional benefit from ChondroFiller™ consolidates between six and twelve months and has been documented holding — and in some cases continuing to improve — at the three-year mark. The leading prospective knee study, the Jerosch post-market clinical follow-up (PMCF), recorded a mean IKDC score of 80 at 36 months, representing a 32-point gain from pre-treatment baseline — nearly double the threshold widely accepted as a meaningful clinical improvement.

The durability question here is different from asking how long a lubricant or steroid injection lasts. ChondroFiller is designed as a structural repair rather than a palliative top-up: an injectable collagen scaffold placed under ultrasound guidance that recruits the body's own progenitor cells and is progressively replaced by the patient's own repair tissue over one to two years. The intended endpoint is a biological fix, not a temporary effect that wears off.

Across pooled published series at three to five years, 70–85% of suitably selected patients maintain meaningful symptom relief. Reoperation rates of 3–8% compare favourably with figures of up to 41% reported for microfracture in similar cohorts.

Those figures come with an important caveat: results are strongly conditional on patient selection. Advanced osteoarthritis substantially reduces the likelihood of a good outcome, and an individual assessment is needed to determine whether this treatment is appropriate.

Why this scaffold is designed to last

The mechanism begins the moment the collagen solution is placed into the defect under ultrasound guidance. ChondroFiller™ is a cell-free Type I collagen hydrogel — it contains no donor or laboratory-grown cells. Instead, it polymerises within approximately 3–5 minutes of placement, anchoring to the base and walls of the focal defect to form a dimensionally stable matrix.

That matrix then acts as a chemotactic scaffold, sending biological signals that draw the patient's own progenitor cells — from the surrounding synovium and subchondral bone — into the collagen structure. This process is called acellular matrix-induced chondrogenesis. A 2025 ex vivo osteochondral explant study confirmed that the cell migration is measurable and meaningful: by day 14, DNA content within the scaffold had increased 2.4-fold, providing direct biological evidence that host cell recruitment occurs and is not simply theoretical.

As those recruited cells mature and begin depositing new matrix, the collagen scaffold resorbs progressively over 12 to 24 months. The scaffold effectively hands over its structural role to the patient's own repair tissue, making the intended endpoint a lasting biological change rather than a temporary effect.

This is mechanistically distinct from lubricant injections such as hyaluronic acid, which improve joint-fluid quality but do not interact with the cartilage surface and require repeat courses roughly every six months. Arthrosamid®, a polyacrylamide hydrogel, integrates into the synovial lining and provides durable mechanical cushioning — but it does not promote endogenous repair. ChondroFiller occupies a separate category: its benefit is designed to persist beyond the scaffold itself.

What the evidence shows at each time point

Three to six months

The earliest controlled knee data comes from a 2016 prospective multicenter randomised trial (n=13 ChondroFiller patients), which recorded statistically significant IKDC improvements at three, six, and twelve months versus pre-operative baseline, with no adverse events. The IKDC is a patient-reported knee function score out of 100; a gain of 16.7 points is the widely accepted minimum that patients notice as meaningful. Results in this trial comfortably exceeded that threshold, establishing both the safety baseline and the pattern of early functional gain.

Twelve months

MOCART scores — an MRI-based measure of repair-tissue quality and volume within the defect, also rated 0–100 — rose from a mean of 65.3 at four weeks to 81.6 at one year across European multi-site data, with some series reaching 84.3. Values above 80 indicate more than 80% volumetric fill with tissue well-integrated into the surrounding native cartilage. A 2024 Bulgarian knee cohort (n=17, mean age 31) confirmed significant Lysholm and IKDC gains at three, six, and twelve months; scores did not progress significantly between six and twelve months, indicating that the primary functional improvement consolidates by mid-year even as structural maturation continues.

Thirty-six months

The Jerosch PMCF prospective study is the main knee-specific durability anchor at this time point. Mean IKDC improvement reached 32.4 points — nearly double the 16.7-point meaningful-change threshold — with absolute IKDC reaching 80, consistent with near-normal knee function. Scores held stable or marginally improved between twelve and thirty-six months, rather than declining.

Beyond thirty-six months

No adequately powered knee RCT has yet completed follow-up at 36 months, so head-to-head knee comparisons at that horizon remain inconclusive. The only published ChondroFiller series extending beyond this point is a hip cohort (Grzegorzek 2021, n=26 acetabular lesions): 17 of 21 evaluable patients (81%) achieved good-to-excellent outcomes at three to five years with MRI-confirmed repair tissue. That is hip data. It is informative about the biological durability of the scaffold class, but it does not fill the gap in knee-specific long-term trial evidence.

Who gets the most durable results

Durability is not uniform across all patients, and the clinical data point consistently to the same selection factors that separate sustained benefit from a poor response.

The patients who fare best are typically adults under 50 with an isolated, focal chondral defect — a contained area of cartilage loss, usually a few square centimetres or less — in a knee that is mechanically stable and properly aligned. In this group, there is sufficient viable cartilage and healthy subchondral bone surrounding the defect to support the cell recruitment the scaffold depends on.

Pre-existing osteoarthritis is the most important disqualifying factor. The hip cohort by Grzegorzek (2021) found that patients with Tönnis grade 2–3 OA — representing established joint-space narrowing and bony change — had consistently poor outcomes, a pattern that translates logically to the knee: where surrounding cartilage is itself degenerate, there are fewer healthy progenitor cells available to populate the scaffold, and the biological repair process cannot adequately proceed.

Joint alignment and ligament stability carry similar weight. A varus knee or a ligament-deficient joint concentrates load unevenly across the defect, mechanically stressing the scaffold before it is colonised and integrated. In these cases, addressing the underlying alignment or instability is usually a prerequisite to considering injectable scaffold treatment.

Compliance with the 0–6-week protected weight-bearing protocol is not simply advisory — it is mechanistically necessary. A 2024 biomechanical study confirmed that ChondroFiller is initially unstable under full cyclic loading at this early stage; applying normal joint forces before stable tissue ingrowth is established risks scaffold displacement before cell colonisation has occurred.

A consultant assessment, including MRI review to characterise defect size, depth, and surrounding tissue quality, is needed to determine individual suitability before proceeding.

How ChondroFiller durability compares to other knee injections

Each injection option in common clinical use targets a different problem at a different level of tissue biology — which is why durability horizons differ so markedly between them.

Corticosteroid addresses acute joint inflammation. Relief typically spans weeks to a few months, which makes it appropriate for an acute flare or pre-procedure optimisation rather than a repeating maintenance strategy. A 2017 JAMA randomised trial (McAlindon et al.) found that triamcinolone given every three months over two years was associated with significantly greater cartilage volume loss compared with saline — a finding that now shapes how repeated corticosteroid courses are approached in clinical practice.

Hyaluronic acid suits patients with mild-to-moderate symptoms who are not yet at the threshold for structural intervention. Its typical durability window of roughly six months reflects its palliative mechanism: lubrication and pain modulation rather than tissue repair. When the clinical aim is structural defect fill, it is not the appropriate choice.

Arthrosamid® (polyacrylamide hydrogel) integrates permanently into the synovial lining and cushions the joint for approximately two to three years. Its best-fit profile differs meaningfully from ChondroFiller: it is designed for established knee OA with diffuse cartilage thinning rather than a focal, contained defect. Because it does not biodegrade, it requires no cell recruitment to sustain its effect — but equally, it does not attempt structural restoration of the defect.

PRP is regenerative in intent, delivering a concentration of growth factors to support the joint's biological environment, and carries a strong evidence base for early-to-moderate knee OA. It does not, however, place a structural matrix within the defect; its role is biological support rather than physical scaffold.

ChondroFiller is currently the only outpatient injectable that provides a physical scaffold within the defect itself and is specifically designed to recruit the patient's own progenitor cells to restore the cartilage layer through acellular matrix-induced chondrogenesis. For a focal defect in a well-selected knee, that distinction determines both the biological endpoint and the basis for durable benefit.

What to expect after your injection and when to review

The recovery follows a predictable biological arc, and understanding what each phase feels like in practice helps manage expectations alongside the clinical timeline.

Weeks 0–6 are the scaffold's most vulnerable window. The protected weight-bearing protocol described in the selection section is mechanistically essential rather than precautionary — the collagen matrix needs time to anchor before it can withstand normal joint loads. Most patients find this period manageable; the treatment is outpatient and does not involve surgical wound recovery.

Months 1–6 bring gradual functional improvement. Some patients notice earlier gains — reduced discomfort on stairs, better walking tolerance — by weeks six to twelve. Progress at this stage is incremental rather than sudden, and slow early change does not predict a poor long-term result.

Months 6–12 typically mark functional stabilisation. As the 2024 Bulgarian knee cohort found, IKDC and Lysholm scores tend to plateau across this interval. Structural MRI, however, continues to show tissue maturation during this window — cartilage infill and integration are still progressing even when symptoms feel stable. The two timelines run independently of one another.

36 months is the primary durability checkpoint in published knee data. The Jerosch PMCF study documented sustained — and in some cases still-improving — functional scores at this point. A structured review, including repeat imaging where there is clinical reason, is appropriate at or around this mark.

Worsening pain, new swelling, mechanical symptoms such as locking or giving way, or failure to progress by six months all warrant earlier reassessment — ideally with repeat imaging rather than clinical impression alone.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1